A Phase III, randomized, two armed, multicenter, parallel, double blind (patient and assessor blinded), active controlled non inferiority clinical trial to determine the non inferior therapeutic efficacy and safety between Beta erythropoietin ®(CinnaPoietin) and Eprex® (epoetin alpha) on treatment of anemia in chronic kidney disease (CKD) hemodialysis patients

Trial Profile

A Phase III, randomized, two armed, multicenter, parallel, double blind (patient and assessor blinded), active controlled non inferiority clinical trial to determine the non inferior therapeutic efficacy and safety between Beta erythropoietin ®(CinnaPoietin) and Eprex® (epoetin alpha) on treatment of anemia in chronic kidney disease (CKD) hemodialysis patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Epoetin alfa (Primary) ; Epoetin alfa (Primary) ; Epoetin beta (Primary) ; Epoetin beta (Primary)
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors CinnaGen
  • Most Recent Events

    • 21 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top